Zenas BioPharma, Inc. ZBIO 深 滬
已收盤 04-02 16:00:00 美东时间
21.46
+1.100
+5.40%
華盛通- 最 高22.15
- 今 開20.12
- 成交量 172.26万股
- 最 低 19.81
- 昨 收 20.36
- 總市值 13.38亿
- 52周最高 44.60
- 市盈率 靜 --
- 換手率 2.76%
- 52周最低 7.34
- 委 比 -36.27%
- 總股本 6237.10万
- 歷史最高 44.60
- 量 比 0.92
- 振 幅 11.49%
- 歷史最低 5.83
- 每 手 1
- 風險率 9.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zenas BioPharma shares are trading lower after the company announced it commenced an underwritten public offering of convertible senior notes and shares of its common stock.
Zenas BioPharma shares are trading lower after the company announced it commenc...
03-27 04:35
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
03-17 18:54
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(4.54) per share. This is a 260.32 percent decrease over losses of $(1.26) per share from the same period last year.
03-16 19:22
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
Zenas Biopharma Highlights Results From Phase 2 MoonStone Trial Of Obexelimab In RMS In Late-Breaking Oral Presentation At ACTRIMS Forum 2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -- Separately announced 24-week data support the robust
02-09 20:15
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
01-10 21:31
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Morgan Stanley Downgrades Zenas BioPharma to Equal-Weight, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer downgrades Zenas BioPharma (NASDAQ:ZBIO) from Overweight to Equal-Weight and lowers the price target from $37 to $19.
01-06 23:44
